Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Nivolumab and ipilimumab

Details

Generic Name:
Nivolumab and ipilimumab
Project Status:
Pending
Therapeutic Area:
Unresectable or advanced hepatocellular carcinoma (HCC)
Manufacturer:
Bristol Myers Squibb Canada Co. (BMS)
Call for patient/clinician input open:
Brand Name:
Opdivo and Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0420-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Opdivo®, in combination with ipilimumab for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Opdivo®, in combination with ipilimumab for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : April 9, 2025